Andrographolide attenuates pulmonary fibrosis by covalently targeting Ptges3 and disrupting the Ptges3-Hsp90-NF-κB axis - PubMed
a day ago
- #Andrographolide
- #Pulmonary Fibrosis
- #NF-κB signaling
- Andrographolide (AP) attenuates pulmonary fibrosis by covalently targeting Ptges3 at Cys58, inhibiting its enzymatic activity and reducing prostaglandin E2 production.
- AP disrupts the Ptges3-Hsp90 chaperone complex, leading to suppression of NF-κB signaling, which is crucial for its anti-inflammatory and antifibrotic effects.
- Genetic knockdown of Ptges3 diminishes the therapeutic efficacy of AP in mouse models, confirming Ptges3 as a critical functional target for treating idiopathic pulmonary fibrosis.